XTX Topco Ltd Takes $228,000 Position in Aquestive Therapeutics, Inc. (NASDAQ:AQST)

XTX Topco Ltd purchased a new position in Aquestive Therapeutics, Inc. (NASDAQ:AQST - Free Report) during the 1st quarter, according to its most recent 13F filing with the SEC. The firm purchased 78,522 shares of the company's stock, valued at approximately $228,000. XTX Topco Ltd owned about 0.08% of Aquestive Therapeutics as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Summit Wealth & Retirement Planning Inc. acquired a new position in shares of Aquestive Therapeutics in the 1st quarter valued at $29,000. Victory Capital Management Inc. acquired a new position in Aquestive Therapeutics in the first quarter valued at about $31,000. Cambridge Investment Research Advisors Inc. bought a new stake in shares of Aquestive Therapeutics in the first quarter worth about $33,000. Two Sigma Advisers LP bought a new stake in shares of Aquestive Therapeutics in the fourth quarter worth about $57,000. Finally, Penbrook Management LLC acquired a new stake in shares of Aquestive Therapeutics during the first quarter worth about $65,000. 32.45% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on AQST shares. Oppenheimer started coverage on Aquestive Therapeutics in a research note on Monday, June 2nd. They set an "outperform" rating and a $7.00 target price for the company. HC Wainwright reissued a "buy" rating and set a $10.00 price objective on shares of Aquestive Therapeutics in a research report on Tuesday, June 17th. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat, Aquestive Therapeutics has a consensus rating of "Buy" and a consensus target price of $10.14.

Aquestive Therapeutics Stock Performance

NASDAQ:AQST remained flat at $4.11 during trading hours on Friday. The company's stock had a trading volume of 1,701,734 shares, compared to its average volume of 1,235,658. Aquestive Therapeutics, Inc. has a 52-week low of $2.12 and a 52-week high of $5.80. The stock has a market capitalization of $409.85 million, a PE ratio of -5.87 and a beta of 1.99. The company's fifty day simple moving average is $3.77 and its 200 day simple moving average is $3.15.

Aquestive Therapeutics (NASDAQ:AQST - Get Free Report) last announced its quarterly earnings data on Monday, August 11th. The company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.18) by $0.04. The company had revenue of $10.00 million during the quarter, compared to the consensus estimate of $11.32 million. Analysts forecast that Aquestive Therapeutics, Inc. will post -0.46 EPS for the current year.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.